Swiss rare disease biopharma Relief Therapeutics withdraws $25 million US IPO
Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, withdrew its plans for an initial public offering on Tuesday. It had filed to raise $25 million by offering 4.2 million units at a price range of $5.50 to $6.50, with each unit consisting of one ADS and one warrant to purchase three-quarters of an ADS, exercisable at 120% of the IPO...read more
